|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MKRN2 |
Gene summary for MKRN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MKRN2 | Gene ID | 23609 |
| Gene name | makorin ring finger protein 2 | |
| Gene Alias | HSPC070 | |
| Cytomap | 3p25.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9H000 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23609 | MKRN2 | LZE24T | Human | Esophagus | ESCC | 9.07e-09 | 1.28e-01 | 0.0596 |
| 23609 | MKRN2 | P2T-E | Human | Esophagus | ESCC | 2.42e-13 | 1.57e-01 | 0.1177 |
| 23609 | MKRN2 | P4T-E | Human | Esophagus | ESCC | 5.21e-10 | 1.71e-01 | 0.1323 |
| 23609 | MKRN2 | P5T-E | Human | Esophagus | ESCC | 1.96e-19 | 4.70e-01 | 0.1327 |
| 23609 | MKRN2 | P8T-E | Human | Esophagus | ESCC | 9.80e-14 | 1.11e-01 | 0.0889 |
| 23609 | MKRN2 | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 7.17e-02 | 0.1131 |
| 23609 | MKRN2 | P10T-E | Human | Esophagus | ESCC | 4.78e-19 | 1.92e-01 | 0.116 |
| 23609 | MKRN2 | P12T-E | Human | Esophagus | ESCC | 6.85e-16 | 2.78e-01 | 0.1122 |
| 23609 | MKRN2 | P15T-E | Human | Esophagus | ESCC | 9.37e-08 | 1.98e-01 | 0.1149 |
| 23609 | MKRN2 | P16T-E | Human | Esophagus | ESCC | 3.01e-10 | 2.49e-01 | 0.1153 |
| 23609 | MKRN2 | P17T-E | Human | Esophagus | ESCC | 4.86e-02 | 2.14e-01 | 0.1278 |
| 23609 | MKRN2 | P19T-E | Human | Esophagus | ESCC | 4.73e-04 | 4.20e-01 | 0.1662 |
| 23609 | MKRN2 | P20T-E | Human | Esophagus | ESCC | 2.00e-15 | 3.36e-01 | 0.1124 |
| 23609 | MKRN2 | P21T-E | Human | Esophagus | ESCC | 5.94e-13 | 1.76e-01 | 0.1617 |
| 23609 | MKRN2 | P22T-E | Human | Esophagus | ESCC | 1.20e-14 | 1.27e-01 | 0.1236 |
| 23609 | MKRN2 | P23T-E | Human | Esophagus | ESCC | 3.25e-17 | 4.32e-01 | 0.108 |
| 23609 | MKRN2 | P24T-E | Human | Esophagus | ESCC | 1.40e-16 | 1.75e-01 | 0.1287 |
| 23609 | MKRN2 | P26T-E | Human | Esophagus | ESCC | 2.16e-20 | 2.94e-01 | 0.1276 |
| 23609 | MKRN2 | P27T-E | Human | Esophagus | ESCC | 1.19e-11 | 2.23e-01 | 0.1055 |
| 23609 | MKRN2 | P28T-E | Human | Esophagus | ESCC | 4.46e-11 | 2.00e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MKRN2 | SNV | Missense_Mutation | rs751152524 | c.1051N>A | p.Asp351Asn | p.D351N | Q9H000 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| MKRN2 | SNV | Missense_Mutation | rs750943574 | c.148C>T | p.Arg50Trp | p.R50W | Q9H000 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MKRN2 | SNV | Missense_Mutation | c.1103N>T | p.Gly368Val | p.G368V | Q9H000 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MKRN2 | SNV | Missense_Mutation | c.92N>T | p.Ser31Ile | p.S31I | Q9H000 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MKRN2 | SNV | Missense_Mutation | novel | c.996N>T | p.Gln332His | p.Q332H | Q9H000 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| MKRN2 | SNV | Missense_Mutation | rs753370925 | c.472N>A | p.Val158Met | p.V158M | Q9H000 | protein_coding | tolerated(0.1) | benign(0.046) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MKRN2 | SNV | Missense_Mutation | novel | c.1132N>T | p.Leu378Phe | p.L378F | Q9H000 | protein_coding | tolerated(0.4) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MKRN2 | SNV | Missense_Mutation | novel | c.957A>T | p.Lys319Asn | p.K319N | Q9H000 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MKRN2 | SNV | Missense_Mutation | novel | c.1189G>A | p.Asp397Asn | p.D397N | Q9H000 | protein_coding | deleterious(0.02) | benign(0.361) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| MKRN2 | SNV | Missense_Mutation | novel | c.745N>A | p.Ala249Thr | p.A249T | Q9H000 | protein_coding | tolerated(0.09) | benign(0.243) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |